MedTrace Logo

Bevacizumab Beyond Progression (BBP)

NCT01740258 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-01-26

Study results available
· View outcomes & findings →

Summary

Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by patients. This study seeks to investigate the use of bevacizumab with the standard therapy (radiation therapy and temozolomide) in newly diagnosed patients, followed by bevacizumab and temozolomide with the continuation of bevacizumab following progression. Two critical questions remain- the role of bevacizumab maintenance and bevacizumab at the time of progression in a patient previously treated with bevacizumab at the time of initial diagnosis.

Conditions

  • Malignant Glioma
  • Grade 4 Malignant Glioma
  • Glioblastoma
  • Gliosarcoma

Interventions

RADIATION

Radiation Therapy

DRUG

Temozolomide

DRUG

Bevacizumab

Sponsors & Collaborators

Principal Investigators

  • Annick Desjardins, MD, FRCPC · Duke Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2019-11-14
Completion
2019-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740258 on ClinicalTrials.gov